Tumor suppressor HIPK2 regulates malignant growth via phosphorylation of NOTCH

Cancer Research

Volumn 76, Issue 16, 2016, Pages 4728-4740

  Ann, Eun Jung ^a   Kim, Mi Yeon ^a,b   Yoon, Ji Hye ^a   Ahn, Ji Seon ^a   Jo, Eun Hye ^a   Lee, Hye Jin ^a   Lee, Hyun Woo ^c   Kang, Hyeok Gu ^c   Choi, Dong Wook ^d   Chun, Kyung Hee ^c   Lee, Ji Shin ^e   Choi, Cheol Yong ^d   Ferrando, Adolfo A ^b   Lee, Keesook ^a   Park, Hee Sae ^a  

^a Chonnam National University   (South Korea)

^b Department of Medicine   (United States)

^c Yonsei University College of Medicine   (South Korea)

^d Sungkyunkwan University   (South Korea)

^e Chonnam National University Medical School   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CAMPTOTHECIN; CISPLATIN; DOXORUBICIN; ETOPOSIDE; FBW7 UBIQUITIN LIGASE; HOMEODOMAIN INTERACTING PROTEIN KINASE 2; NOTCH1 RECEPTOR; TUMOR SUPPRESSOR PROTEIN; UBIQUITIN PROTEIN LIGASE; UNCLASSIFIED DRUG; CARRIER PROTEIN; HIPK2 PROTEIN, HUMAN; NOTCH1 PROTEIN, HUMAN; PROTEIN SERINE THREONINE KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; CARCINOGENESIS; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN MOTIF; PROTEIN PHOSPHORYLATION; PROTEIN STABILITY; SIGNAL TRANSDUCTION; SOMATIC MUTATION; TUMOR GROWTH; ANIMAL; BREAST TUMOR; CELL PROLIFERATION; CELL SURVIVAL; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; GENETICS; IMMUNOBLOTTING; IMMUNOPRECIPITATION; METABOLISM; MUTATION; PATHOLOGY; PHOSPHORYLATION; PHYSIOLOGY; POLYMERASE CHAIN REACTION; TUMOR INVASION; WESTERN BLOTTING; XENOGRAFT;

ANIMALS; BLOTTING, WESTERN; BREAST NEOPLASMS; CARRIER PROTEINS; CELL PROLIFERATION; CELL SURVIVAL; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HETEROGRAFTS; HUMANS; IMMUNOBLOTTING; IMMUNOPRECIPITATION; MICE; MUTATION; NEOPLASM INVASIVENESS; PHOSPHORYLATION; POLYMERASE CHAIN REACTION; PROTEIN STABILITY; PROTEIN-SERINE-THREONINE KINASES; RECEPTOR, NOTCH1;

EID: 84982168624     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-15-3310     Document Type: Article

References (32)

1. Artavanis-Tsakonas S, Rand MD, Lake RJ. Notch signaling: cell fate control and signal integration in development. Science 1999;284: 770-6.
2. Pece S, Serresi M, Santolini E, Capra M, Hulleman E, Galimberti V, et al. Loss of negative regulation by Numb over Notch is relevant to human breast carcinogenesis. J Cell Biol 2004;167:215-21.
3. Reedijk M, Odorcic S, Chang L, Zhang H, Miller N, McCready DR, et al. High-level coexpression of JAG1 and NOTCH1 is observed in human breast cancer and is associated with poor overall survival. Cancer Res 2005;65:8530-7.
4. Stylianou S, Clarke RB, Brennan K. Aberrant activation of notch signaling in human breast cancer. Cancer Res 2006;66:1517-25.
5. Rizzo P, Miao H, D'Souza G, Osipo C, Song LL, Yun J, et al. Cross-talk between notch and the estrogen receptor in breast cancer suggests novel therapeutic approaches. Cancer Res 2008;68:5226-35.
6. Dievart A, Beaulieu N, Jolicoeur P. Involvement of Notch1 in the development of mouse mammary tumors. Oncogene 1999;18: 5973-81.
7. Koch U, Radtke F. Notch and cancer: a double-edged sword. Cell Mol Life Sci 2007;64:2746-62.
8. Al-Hussaini H, Subramanyam D, Reedijk M, Sridhar SS. Notch signaling pathway as a therapeutic target in breast cancer. Mol Cancer Ther 2011;10:9-15.
9. Garber K. Notch emerges as new cancer drug target. J Natl Cancer Inst 2007;99:1284-5.
10. Hubbard EJ, Wu G, Kitajewski J, Greenwald I. sel-10, a negative regulator of lin-12 activity in Caenorhabditis elegans, encodes a member of the CDC4 family of proteins. Genes Dev 1997;11:3182-93.
11. Gupta-Rossi N, Le Bail O, GonenH, BrouC, Logeat F, Six E, et al. Functional interaction between SEL-10, an F-box protein, and the nuclear form of activated Notch1 receptor. J Biol Chem 2001;276:34371-8.
12. O'Neil J, Grim J, Strack P, Rao S, Tibbitts D, Winter C, et al.FBW7mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase inhibitors. J Exp Med 2007;204:1813-24.
13. Thompson BJ, Buonamici S, Sulis ML, Palomero T, Vilimas T, Basso G, et al. The SCFFBW7 ubiquitin ligase complex as a tumor suppressor in T cell leukemia. J Exp Med 2007;204:1825-35.
14. Demarest RM, Ratti F, Capobianco AJ. It's T-ALL about Notch. Oncogene 2008;27:5082-91.
15. Ann EJ, Kim HY, Choi YH, Kim MY, MoJS, Jung J, et al. Inhibition of Notch1 signaling by Runx2 during osteoblast differentiation. J Bone Miner Res 2011;26:317-30.
16. Mo JS, Ann EJ, Yoon JH, Jung J, Choi YH, Kim HY, et al. Serum-and glucocorticoid-inducible kinase 1 (SGK1) controls Notch1 signaling by downregulation of protein stability through Fbw7 ubiquitin ligase. J Cell Sci 2011;124:100-12.
17. Choi DW, Seo YM, Kim EA, Sung KS, Ahn JW, Park SJ, et al. Ubiquitination and degradation of homeodomain-interacting protein kinase 2 by WD40 repeat/SOCS box protein WSB-1. J Biol Chem 2008;283:4682-9.
18. Welcker M, Clurman BE. FBW7 ubiquitin ligase: a tumour suppressor at the crossroads of cell division, growth and differentiation. Nat Rev Cancer 2008;8:83-93.
19. Yamada D, Perez-Torrado R, Filion G, Caly M, Jammart B, Devignot V, et al. The human protein kinase HIPK2 phosphorylates and downregulates the methyl-binding transcription factor ZBTB4. Oncogene 2009;28:2535-44.
20. Wei G, Ku S, Ma GK, Saito S, Tang AA, Zhang J, et al. HIPK2 represses betacatenin-mediated transcription, epidermal stem cell expansion, and skin tumorigenesis. Proc Natl Acad Sci U S A 2007;104:13040-5.
21. Forbes SA, Bindal N, Bamford S, Cole C, Kok CY, Beare D, et al. COSMIC: mining complete cancer genomes in the catalogue of somatic mutations in cancer. Nucleic Acids Res 2011;39(Database issue): D945-50.
22. Real PJ, Ferrando AA. NOTCH inhibition and glucocorticoid therapy in T-cell acute lymphoblastic leukemia. Leukemia 2009;23:1374-7.
23. Wang Z, Banerjee S, Li Y, Rahman KM, Zhang Y, Sarkar FH. Downregulation of notch-1 inhibits invasion by inactivation of nuclear factorkappaB, vascular endothelial growth factor, and matrix metalloproteinase-9 in pancreatic cancer cells. Cancer Res 2006;66:2778-84.
24. Rinaldo C, Prodosmo A, Siepi F, Soddu S. HIPK2: a multitalented partner for transcription factors in DNA damage response and development. Biochem Cell Biol 2007;85:411-8.
25. D'Orazi G, Cecchinelli B, Bruno T, Manni I, Higashimoto Y, Saito S, et al. Homeodomain-interacting protein kinase-2 phosphorylates p53 at Ser 46 and mediates apoptosis. Nat Cell Biol 2002;4:11-9.
26. Hofmann TG, Moller A, Sirma H, Zentgraf H, Taya Y, Droge W, et al. Regulation of p53 activity by its interaction with homeodomain-interacting protein kinase-2. Nat Cell Biol 2002;4:1-10.
27. Dauth I, Kruger J, Hofmann TG. Homeodomain-interacting protein kinase 2 is the ionizing radiation-activated p53 serine 46 kinase and is regulated by ATM. Cancer Res 2007;67:2274-9.
28. Weng AP, Ferrando AA, Lee W, Morris JPt, Silverman LB, Sanchez-Irizarry C, et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 2004;306:269-71.
29. Roy M, Pear WS, Aster JC. The multifaceted role of Notch in cancer. Curr Opin Genet Dev 2007;17:52-9.
30. Li N, Fassl A, Chick J, Inuzuka H, Li X, Mansour MR, et al. Cyclin C is a haploinsufficient tumour suppressor. Nat Cell Biol 2014;16:1080-91.
31. Oberg C, Li J, Pauley A, Wolf E, Gurney M, Lendahl U. The Notch intracellular domain is ubiquitinated and negatively regulated by the mammalian Sel-10 homolog. J Biol Chem 2001;276:35847-53.
32. WuG, Lyapina S, Das I, Li J, Gurney M, Pauley A, et al. SEL-10 is an inhibitor of notch signaling that targets notch for ubiquitin-mediated protein degradation. Mol Cell Biol 2001;21:7403-15.